Background. Little is known about innate lymphoid cell (ILC) populations in the human gut, and the turnover of these cells and their subsets after transplantation has not been described. Methods. Intestinal samples were taken from 4 isolated intestine and 3 multivisceral transplant recipients at the time of any operative resection, such as stoma closure or revision. ILCs were isolated and analyzed by flow cytometry. The target population was defined as being negative for lineage markers and double-positive for CD45/CD127. Cells were further stained to define ILC subsets and a donor-specific or recipient-specific HLA marker to analyze chimerism. Results. Donor-derived ILCs were found to persist greater than 8 years after transplantation. Additionally, the percentage of cells thought to be lymphoid tissue inducer cells among donor ILCs was far higher than that among recipient ILCs. Conclusions. Our findings demonstrate that donor-derived ILCs persist long-term after transplantation and support the notion that human lymphoid tissue inducer cells may form in the fetus and persist throughout life, as hypothesized in rodents. Correlation between chimerism and rejection, graft failure, and patient survival requires further study.
A pproximately 100 to 200 intestinal or multivisceral transplants (MvTx) are performed each year in the United States for either short gut syndrome or malabsorption resulting from a range of enteropathies. 1 Until recently, nothing was known about turnover of donor graft resident hematopoietic cells after intestinal transplantation. We and others have shown that donor lymphocytes persist to varying degrees after intestinal and multivisceral transplantation. [2] [3] [4] [5] A recent report has characterized the phenotypes of innate lymphoid cells (ILCs) found in the gut after transplantation. 6 However, currently there is no published information about recipient replacement of donor ILCs after transplantation. ILCs are a relatively recently characterized family of cells that play a variety of important roles within the innate immune system. Although still incompletely understood, they are "lineage negative" cells within the lymphocyte gate on flow cytometry that are double positive for CD45 and CD127 and have been divided into 3 groups (ILC1, ILC2, and ILC3), each of whose functions, lineage-defining transcription factors, and cytokines corresponds with 1 of the T-helper cell subsets (Th1, Th2, and Th17 respectively). 7 Briefly, ILC1s express the transcription factor T-bet, include classical natural killer (NK) cells as well as a noncytotoxic subset of cells, secrete IFN-γ in response to IL-12 and IL-18, and promote immune responses to intracellular bacteria and parasites. [8] [9] [10] [11] ILC2s express the transcription factors GATA3 and RORα; consist of nuocytes, natural helper cells, and innate helper 2 cells; are mostly found in mesenteric lymph nodes, fatassociated lymphatic clusters, and lung; release IL-4, IL-5, IL-9, and IL-13 in response to IL-25, IL-33, and thymic stromal lymphopoietin; and play a role in allergy, tissue repair, and the immune response to helminths and other extracellular parasites. [12] [13] [14] [15] ILC3s express the transcription factor RORγt; consist of lymphoid tissue inducer (LTi) cells as well as non-LTi cells differentiated by their expression of the natural cytotoxicity receptor (NCR) NKp46; secrete IL-17, IL-22, GM-CSF, TNF, and IFN-γ in response to IL-2, IL-7, IL-1β, and IL-23; and play a role in guiding formation of lymphoid follicles, tissue defense, and inflammation. 9, 16, 17 Little is known about the physiology and ontogeny of ILCs in humans. Intestinal transplantation provides an opportunity to shed light on these features, because the use of HLA allele group-specific monoclonal antibodies to distinguish donor and recipient lymphocytes allows the kinetics of ILC replacement by the recipient to be examined. ILC turnover could be relevant to posttransplant de novo inflammatory bowel disease (IBD), which occurs at a high rate after intestinal transplantation and in which ILCs have been implicated. 18, 19 Therefore, using HLA markers to distinguish donor-derived and recipient-derived cells, we investigated the turnover of donor ILCs in intestinal grafts after intestinal and multivisceral transplantation.
MATERIALS AND METHODS

Intestinal Specimens
Intestinal specimens were collected from biopsies performed for clinical purposes or from resected portions from stoma revisions or closures. All transplant recipients consented to their participation in this study under an IRB-approved protocol. HLA typing was performed for clinical purposes by the clinical lab at our facility as part of the preparation for transplantation. Episodes of rejection were defined as such by the pathologist reading biopsies performed for clinical reasons.
Specimen Processing
Intestinal biopsies were cut into small pieces, and the mucosa was sharply divided from the underlying tissue. The mucosal specimens were placed in 30 to 50 mL of medium containing RPMI (Gibco, Life Technologies, Grand Island, NY) with 1 mg/mL collagenase D (Roche, Indianapolis, IN) and 50 μg/mL DNAse (Sigma-Aldrich, St. Louis, MO) on a shaker for 2 hours at 37°C. The resulting suspension was filtered through a 40-micron nylon mesh filter and counted in Trypan Blue (Gibco, Life Technologies) diluted 1:1 with phosphatebuffered saline (Fisher Scientific, Pittsburgh, PA).
Staining
Cells were resuspended in FACS medium containing 95% phosphate-buffered saline, 5% fetal bovine serum (Gibco, Life Technologies), and 1 g/L sodium azide (Sigma-Aldrich). Cells were stained for 30 minutes and then washed and resuspended in 100 to 300 μL of FACS medium. The following antibodies to human proteins were used. From BioLegend (San Diego, CA): phycoerythrin (PE)-conjugated anti-CD19 (HIB19); biotinconjugated anti-CD3 (OKT3), anti-CD5 (UCHT2), anti-CD8 (SK1), anti-CD19 (HIB19), and anti-CD11b (ICRF44); brilliant violet (BV) 421-conjugated streptavidin; BV650-conjugated anti-CD45 (HI30); BV711-conjugated anti-CD127 (A019D5); BV510-conjugated and BV421-conjugated anti-CD117 (cKit, 104D2); BV510-conjugated IL-17A (BL168); and BV605-conjugated anti-CD56 (NCAM). From Becton Dickinson (BD, East Rutherford, NJ): PE-conjugated anti-CD11b (ICRF44); allophycocyanin (APC)-conjugated anti-pan class I (G46-2.6); APC-Cy7-conjugated anti-CD8 (SK1); V500-conjugated anti-CD45 (HI30); phycoerythrin-Cy7 (PE-Cy7)-conjugated anti-CD127 (HIL-7R-M21); PerCP-Cy5.5-conjugated CD3 (SP34-2). From One Lambda (Canoga Park, CA): fluorescein isothiocyanate (FITC)-conjugated anti-HLA A2/A28; anti-HLA A9; and anti-HLA B8. See Table S1 , SDC (http://links.lww.com/TP/B378) for a full list of antibodies. If biotin stains were used, cells were washed twice and then stained for 15 minutes with the secondary stain followed by a final wash. For intracellular staining, samples were incubated in fixation and permeabilization buffers after primary staining according to the manufacturer's instructions (eBioscience, San Diego, CA). All nonpermeabilized samples received 10 μL of 4′,6-diamidino-2-phenylindole (Invitrogen, Life Technologies, Grand Island, NY) to stain dead cells just before acquisition. Cells were acquired on a BD LSRII (Becton Dickenson, East Rutherford, NJ). FACS results were analyzed using FlowJo version 9.5.3 (Tree Star, Ashland, OR).
RESULTS
ILC Analyses From Patient Graft Biopsies
A total of 14 recipients of either isolated intestinal transplant (ITx) or MvTx were eligible for our study. The percentage of ILCs in each sample was so small that only large specimens (eg, from time of stoma closure or revision) could be analyzed for ILC chimerism. Seven patients (patients 5, 6, 7, 8, 9, 13, and 14) had large enough graft samples available to permit such analysis. The timepoints for biopsies from each patient are listed in Table 1 . HLA-specific markers were chosen based on differences in donor and recipient HLA (see Table S1 , SDC, http:// links.lww.com/TP/B378).
To identify ILCs, we first gated the lineage negative (negative for a combination of CD3, CD8, CD11b, CD19, and in certain samples, CD5) population within the lymphocyte gate ( Figures 1A-D) . Among the lineage negative cells, we then gated on CD45/CD127 double-positive cells (Figure 1E ), which were defined as ILCs. 8, 12, 20 Of note, patient 14's sample was from colon, whereas all others were ileum. The gating for patient 14 also used a modified panel, in which live CD45+ cells were first gated and lineage positive cells were then excluded on the basis of staining for CD3, CD5, CD11b, CD11c, CD14, and CD19. ILCs were then considered to be cells that stained with a pan-HLA class 1 marker and CD127.
ILC chimerism was then determined by assessing HLA class I expression by a pan anti-class I antibody versus an HLA allele group-specific marker. For patients 5, 6, 8, 13 , and 14, recipient cells were distinguished from donor by HLA A2/A28 expression. For patient 7, donor but not recipient cells expressed HLA B8. For patient 9, recipient but not donor cells expressed HLA A9. Figure 1F shows a representative chimerism plot.
ILC subpopulations were gated based on surface staining. ILC3s express cKit. 21 ILC3s expressing CD56 were defined as NCR+ ILC3s (NKp46), approximately half of which express CD56, while CD56-negative ILC3s were considered to be either LTi cells or the half of NCR+ ILC3s that do not express CD56. 11, 21 For the purposes of this paper, these cKit-positive/CD56-negative ILC3s will be referred to as CD56 neg ILC3s. ILCs that were cKit-negative were considered to be ILC1s. 21 While these might represent classical NK cells, it is increasingly thought that conventional NK cells are CD127-negative and these CD127+/CD56+ cells are NCR+ ILCs. 7 Figures 1G-H show these different subpopulations.
ILC and T Cell Chimerism
The number of ILCs identified among the 10 samples from 7 recipients ranged from 29 to 1781 (mean, 560.1; SD, 661.2). The sample from patient 14 was the only to include fewer than 100 cells, with no other sample lower than 116 cells (Table 1) . A range of 1.0% to 62.9% of ILCs in our specimens were donor-derived. There was no correlation between type of transplant (ITx versus MvTx) and chimerism. Donor-derived ILCs persisted long-term in many specimens. In the specimen taken longest after transplantation (patient 8, 8 years), 33.8% of ILCs were still of donor origin. In this and 2 other patients (patients 13 and 14), donor ILCs persisted longer than donor T alpha-beta cell subsets (CD4, CD8) in the graft (Table 1) . In others (patients 5 and 7), ILC replacement by the recipient was greater than that of CD4 and CD8 T cells in the same specimens. Gamma-delta T cell replacement by the recipient was highly variable and did not always correlate with other T cell subsets (Table 1 ). In the 2 patients from whom more than 1 sufficiently large biopsy was available for ILC analysis, recipient replacement of ILCs increased between days 322 and 622 in 1 (patient 6) and decreased between days 251 and 303 in the other (patient 7).
Six of the 7 patients undergoing ILC analysis had rejection at various times. The 1 patient with no rejection (patient 5) still had approximately 31% donor ILCs just after 1 year posttransplant. However, 2 patients with even higher donor ILC persistence (patients 7 and 8) had rejection episodes and chronic humoral rejection, respectively (Table 1) . Thus, no correlation between rejection and ILC replacement by the recipient could be identified from this limited sample. Figure 1 shows the representative gating of ILC subsets from one patient (patient 6 on POD 322). ILC1s and NCR + ILC3s were detectable in all specimens. CD56 neg ILC3s (which include LTi cells and the half of NCR+ ILC3s not expressing CD56) were detectable in only 5 of 9 specimens in 4 of 6 patients. In 3 of the 4 patients in whom CD56 neg ILC3s were detectable in some or all specimens, the percentage of CD56 neg ILC3s cells among donor ILCs was much higher than that among recipient ILCs (Figure 2A ). The donor chimerism in CD56 neg ILC3s was greater than that in the other ILC subsets in 4 of 5 LTi-containing specimens obtained from 6 patients ( Figure S1 , SDC, http://links.lww.com/TP/B378). Overall, these data suggest that donor LTi cells may persist longer than other donor ILCs.
ILC Subsets
In contrast to the CD56 neg ILC3 subset, other ILC3s comprised a much greater percentage of recipient ILCs than they did of donor ILCs in almost all samples ( Figure 2B ). In addition, the percentage of non-CD56 neg ILC3s among donor ILCs decreased in serial biopsies from 2 patients, although the percentage of such cells among total and recipient ILCs also decreased in the same samples ( Figure 2B ). The percentage of ILC1s among recipient and donor ILC populations showed no trend ( Figure 2C) .
DISCUSSION
This study, to our knowledge, is the first to characterize the chimerism of ILCs in the gut after intestinal or multivisceral transplantation. Our major findings are: (1) that ILCs can be identified in transplanted gut and characterized as being either recipient or donor in origin; (2) that donor-derived ILCs can persist in transplanted gut for many years, in some cases longer than donor T cells; and (3) that type 3 donor ILCs, particularly CD56 neg ILC3s cells, may persist longer than other subsets.
The latter observation is consistent with observations in mice and the hypothesis that LTi cells (which are included in the CD56 neg ILC3s) form in humans during the fetal period and persist throughout life with little turnover, seeding the formation of lymphoid follicles. 20, [22] [23] [24] In contrast, ILC1s are not found in fetal gut and develop only after colonization of the gut with commensals, thereby playing a role in the innate response against luminal bacteria. 8 Considering these observations, it makes ontological sense that CD56 neg ILC3s predominate among donor lymphocytes persisting in transplanted gut years after transplantation. However, we recognize that our samples are limited by possible variations in cell composition from different sample sites and by the dearth of donor CD56 neg ILC3s found after transplantation in some cases. In future experiments, the inclusion of NKp46 in our panel, which was not available to us at the time of these studies, will help delineate LTi cells from other ILC3s.
Our data raise questions about the pathophysiology of de novo IBD after intestinal transplantation, which has been shown to occur at a rate up to 10-fold higher than in the general population. 18, 25, 26 Recent evidence has shown that inflammatory disease in the gut is largely mediated by ILCs, particularly ILC3s. 19 Specifically, the dysregulation of Th17 cytokines, which are expressed by ILC3s, is thought to contribute to the development of IBD and other inflammatory and autoimmune conditions. 27 Similarly, dysregulation of the Th1 response, driven by the transcription factor T-bet and characterized by IFN-γ secretion, has been associated with rejection after ITx. 26, 28 More detailed analyses in additional patients might reveal associations between these phenomena and the turnover and function of various ILC populations.
Our report is one of few to present a panel for identifying human ILCs in the gut, as well as their possible subsets, and is the first to show that this can be done with HLAspecific staining to assess chimerism. This has been done previously for investigation of chimerism in peripheral blood after transplantation by our group, 28 but previous investigation of chimerism in transplanted intestinal tissue has instead relied on genetic analysis via fluorescent in situ hybridization, polymerase chain reaction, or immunohistochemistry. 4, 5, 30, 31 Our method allows dynamic and in depth analysis of ILC chimerism and phenotyping.
Our analysis is constrained by the small series studied and the relative paucity of ILCs (especially in the sample from Patient 14) , which limits us to very large tissue samples, such as those at stoma closure or resection rather than those from routine biopsies. It has also been difficult to confirm our ILC subset definitions due to the small number of ILCs in our samples, making it difficult to isolate even small subpopulations. Moreover, the ILC panel stains significantly less clearly after the permeabilization that is required for cytokine or transcription factor staining. However, even without these confirmatory studies, we can identify subpopulations from their surface markers with a reasonable degree of confidence based on individual studies 8, 12, 15, 17, 22, 32 and aggregate phenotyping data assembled in recent expert reviews. 11, 21 Of note, we did not include ILC2-specific surface stains in our panel since these cells are thought to reside in the airway, skin, fat-associated lymphoid clusters, and mesenteric lymph nodes but not in significant numbers in the intestinal lumen. 12, 15 Ultimately, our results indicate that donor ILC chimerism, especially of LTi cells, is capable of persisting long-term after intestinal and multivisceral transplantation, but the significance of this information has yet to be fully understood. Correlation between chimerism and rejection, graft failure, and posttransplant IBD requires further study with more biopsies and more patients.
